A multidisciplinary panel of experts provides an overview of the economic burden of HIV and the role of pre-exposure prophylaxis (PrEP) in preventing HIV transmission. Ian Frank, MD and Jeffrey ...
In their research article published in Eurosurveillance, von Schreeb et al. challenge existing assumptions regarding the relationship between the use of HIV pre-exposure prophylaxis (PrEP) and the ...
HIV pre-exposure prophylaxis (PrEP) is a prevention strategy which includes the regular or event-driven use of antiretroviral medication to prevent HIV infection in adults. Several clinical trials ...
A brand new drug might be more effective at preventing HIV than current methods. Many people take daily oral antiretroviral medication—known as PrEP (pre-exposure prophylaxis)—to protect themselves ...
Oral HIV pre-exposure prophylaxis (PrEP) is highly effective for preventing HIV. Several different developments in the US either threaten to increase or promise to decrease PrEP out-of-pocket costs ...
Pre-exposure prophylaxis (PrEP) is a medication regimen that is used to protect at-risk populations from HIV infection. The FDA approved the drug TRUVADA ...
Black gay men face major PrEP access gaps due to cost, stigma, mistrust, and provider silence—despite high HIV impact; ...
The Centers for Disease Control and Prevention (CDC) has updated its guidance to recommend that doctors more readily prescribe and inform patients about medicine that prevents HIV called pre-exposure ...
MONTRÉAL, March 25, 2025 /CNW/ - ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. (PFE) and Shionogi as shareholders, is pleased to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results